📊 FHTX Key Takeaways
Is FHTX a Good Investment? Thesis Analysis
Foghorn Therapeutics faces severe financial distress with negative stockholders' equity of -$108.5M, indicating liabilities exceed assets by a substantial margin. Despite 36.8% revenue growth, the company burns significant cash with operating losses of -$86.4M and free cash flow of -$86.1M, unsustainable without substantial capital raises or pivotal clinical successes. The negative gross margin environment combined with an accelerating cash burn rate threatens viability if revenue growth cannot rapidly expand or operating expenses are not dramatically reduced.
Why Buy FHTX? Key Strengths
- Revenue growth of 36.8% year-over-year indicates expanding commercial traction
- Adequate current liquidity ratio of 2.73x with $80.9M cash available
- Net loss improving by 14.2% YoY suggests some operational leverage emerging
FHTX Investment Risks to Consider
- Negative stockholders' equity of -$108.5M indicates technical insolvency and balance sheet impairment
- Operating cash burn of -$86.1M annually with only $80.9M cash runway approximately 11-12 months
- Negative operating margin of -279.5% and negative gross margin suggest business model not yet viable at scale
- No long-term debt cushion; company dependent on equity financing or revenue acceleration for survival
- Operating losses (-$86.4M) far exceed revenue ($30.9M), indicating unprofitable operations cannot sustain without external capital
Key Metrics to Watch
- Cash runway and burn rate trajectory - critical for survival assessment
- Path to gross margin breakeven and operating profitability timeline
- Revenue growth sustainability and pipeline advancement for clinical programs
FHTX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.73x current ratio provides a solid financial cushion.
FHTX Profitability Ratios
FHTX vs Healthcare Sector
How Foghorn Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FHTX Overvalued or Undervalued?
Based on fundamental analysis, Foghorn Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FHTX Balance Sheet & Liquidity
FHTX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Foghorn Therapeutics Inc.'s revenue has grown significantly by 2,243% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.58 indicates the company is currently unprofitable.
FHTX Growth Metrics (YoY)
FHTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.8M | -$15.8M | $-0.25 |
| Q2 2025 | $6.9M | -$17.9M | $-0.28 |
| Q1 2025 | $5.1M | -$18.8M | $-0.30 |
| Q3 2024 | $7.8M | -$14.3M | $-0.31 |
| Q2 2024 | $5.6M | -$23.0M | $-0.45 |
| Q1 2024 | $5.1M | -$25.0M | $-0.59 |
| Q3 2023 | $6.6M | -$14.3M | $-0.34 |
| Q2 2023 | $4.5M | -$26.9M | $-0.66 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FHTX Capital Allocation
FHTX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Foghorn Therapeutics Inc. (CIK: 0001822462)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FHTX
What is the AI rating for FHTX?
Foghorn Therapeutics Inc. (FHTX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FHTX's key strengths?
Claude: Revenue growth of 36.8% year-over-year indicates expanding commercial traction. Adequate current liquidity ratio of 2.73x with $80.9M cash available.
What are the risks of investing in FHTX?
Claude: Negative stockholders' equity of -$108.5M indicates technical insolvency and balance sheet impairment. Operating cash burn of -$86.1M annually with only $80.9M cash runway approximately 11-12 months.
What is FHTX's revenue and growth?
Foghorn Therapeutics Inc. reported revenue of $30.9M.
Does FHTX pay dividends?
Foghorn Therapeutics Inc. does not currently pay dividends.
Where can I find FHTX SEC filings?
Official SEC filings for Foghorn Therapeutics Inc. (CIK: 0001822462) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FHTX's EPS?
Foghorn Therapeutics Inc. has a diluted EPS of $-1.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FHTX a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Foghorn Therapeutics Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FHTX stock overvalued or undervalued?
Valuation metrics for FHTX: ROE of N/A (sector avg: 15%), net margin of -240.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FHTX stock in 2026?
Our dual AI analysis gives Foghorn Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FHTX's free cash flow?
Foghorn Therapeutics Inc.'s operating cash flow is $-86.1M, with capital expenditures of $50.0K. FCF margin is -278.7%.
How does FHTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -240.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.73 (avg: 2).